Professor, Pediatrics, Perelman School of Medicine
Pediatric Hematology & Oncology
Dr. John M. Maris, MD
|
|
Give Review
John Maris practices Pediatric Hematology & Oncology. He went to Perelman School of Medicine at the University of Pennsylvania. He over the years received 5 awards: "America's Top Doctors", "Philadelphia Magazine", "America's Top Doctors for Cancer", "Elected Member" and "Super Doctor". Doctor John M. Maris, MD is also published. He has 99 publications published. The lastest publication: "Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes.'
Publications
- Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program.
- MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
- Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.
- Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes.
- Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.
- A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis.
- Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.
- Treatment of neuroblastoma in congenital central hypoventilation syndrome with a PHOX2B polyalanine repeat expansion mutation: New twist on a neurocristopathy syndrome.
- Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism.
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.
- (131)I-Metaiodobenzylguanidine with Intensive Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma. A New Approaches to Neuroblastoma Ther...
- Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®) ) by the Pediatric Preclinical Testing Program (PPTP).
- Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program.
- Common Genetic Variants in NEFL Influence Gene Expression and Neuroblastoma Risk.
- Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program.
- Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.
- Reply to N.-K.V. Cheung et al.
- Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.
- Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.
- Age-Dependent Prognostic Effect by Mitosis-Karyorrhexis Index (MKI) in Neuroblastoma: A Report from the Children's Oncology Group.
- The promises and pitfalls of genetic epidemiologic approaches to pediatric Cancers: Lessons from MDM2.
- The ASPHO 2014 distinguished career award goes to Dr. Beverly Lange.
- Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program.
- Integrating Cell-Based and Clinical Genome-Wide Studies to Identify Genetic Variants Contributing to Treatment Failure in Neuroblastoma Patients.
- Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: A report from the Children's Oncology Group (ANBL0621).
- Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.
- Proton versus photon radiation therapy for patients with high-risk neuroblastoma: the need for a customized approach.
- Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program.
- Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
- Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.
- Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Onco...
- Phase I trial of fenretinide deLivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the new approaches t...
- Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.
- Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consorti...
- Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee.
- Initial Testing (Stage 1) of Eribulin, a Novel Tubulin Binding Agent, by the Pediatric Preclinical Testing Program.
- Targeting MYCN: A Good BET for Improving Neuroblastoma Therapy?
- Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children's Oncology Group.
- The genetic landscape of high-risk neuroblastoma.
- A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1.
- Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program.
- Trans-population Analysis of Genetic Mechanisms of Ethnic Disparities in Neuroblastoma Survival.
- ATF4 Regulates MYC-Mediated Neuroblastoma Cell Death upon Glutamine Deprivation.
- COMBINATION THERAPY TARGETING THE CHK1 AND WEE1 KINASES DEMONSTRATES THERAPEUTIC EFFICACY IN NEUROBLASTOMA.
- Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma.
- Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes Cancer cells to centromere-associated protein E (CENP-E) inhibition.
- New Strategies in Refractory and Recurrent Neuroblastoma: Translational Opportunities to Impact Patient Outcome.
- Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program.
- Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.
- Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.
- Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.
- Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.
- Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a ?-secretase inhibitor targeting notch signaling.
- Pediatric horner syndrome.
- Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program.
- Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program.
- Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program.
- Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.
- Combination testing of cediranib (AZD2171) against childhood Cancer models by the pediatric preclinical testing program.
- Initial testing (stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.
- Safety and efficacy of tandem (131) I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma.
- Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma.
- Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.
- Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric Cancer.
- Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility Loci.
- Initial testing of lenalidomide by the pediatric preclinical testing program.
- Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.
- Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study.
- RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma.
- Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program.
- Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma.
- Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study.
- Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.
- Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha.
- Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.
- Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program.
- Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.
- Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.
- Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.
- Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program.
- Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
- Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.
- Recent advances in neuroblastoma.
- Initial testing of topotecan by the pediatric preclinical testing program.
- Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target.
- Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma.
- Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature.
- Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program.
- Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polyme...
- Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program.
- Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.
- Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program.
- Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG.
- Inhibition of ALK signaling for Cancer therapy.
- Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program.
- Initial testing of aplidin by the pediatric pre-clinical testing program.
- Common variations in BARD1 influence susceptibility to high-risk neuroblastoma.
- Comparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide single nucleotide polymorphism array analysis.
Schools
Perelman School of Medicine University of Pennsylvania
Children39s Hospital Of Philadelphia
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Liver Cancer
- Lung Cancer
- View All
Doctors Specialties
- Pediatric Hematology
- Oncology
Accepted Insurances
- Aetna
- Amerigroup (Wellpoint)
- Local Value Network EPO
- Local Value Network HMO
- Local Value Network HMO+
- Local Value Network POS+
- Local Value Network PPO
- Personal Choice PPO
- Regional Pref Network EPO
- Regional Pref Network HMO
- Regional Pref Network HMO+
- Regional Pref Network POS+
- Regional Pref Network PPO
- Blue Card PPO
- Great West Healthcare-Cigna PPO
- Commercial Insurance Company
- Geisinger Health Plan
- HealthPartners
- Community Blue PPO
- Advance EPO
- Direct Access
- Horizon Blue Cross Blue Shield HMO
- Horizon Blue Cross Blue Shield POS
- Horizon Blue Cross Blue Shield PPO
- Choice Care PPO
- Keystone Health Plan East HMO
- MagnaCare
- Medicaid
- Medicare MCR
- MultiPlan PPO
- Neighborhood Health Plan
- Freedom Plan
- QualCare HMO
- QualCare PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- Oxford Liberty
- United Healthcare
Awards
- America's Top Doctors
- Philadelphia Magazine
- America's Top Doctors for Cancer
- Elected Member
- Super Doctor
Education
-
Children's Hospital of Philadelphia -
Perelman School of Medicine at the University of Pennsylvania
Helpful Reviews
Similar Doctors
|
|
Dr. Robert Iannone, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Jennifer L. Eng, LMSW
This Doctor is OpenDoctor Recommended.
|
|
|
Vandana Batra, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephan A. Grupp, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Nataly Apollonsky, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David T. Teachey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shannon L. Maude, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tammy I. Kang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Naomi J. Balamuth, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carly R. Varela, MD
This Doctor is OpenDoctor Recommended.
|